Revvity Inc. Financial Highlights and Recent Developments

Revvity Inc., a health science solutions provider based in Waltham, has been making significant strides in the health care sector, particularly within life sciences tools and services. Listed on the New York Stock Exchange, the company specializes in multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, and diagnosis. These services cater to pharmaceutical, biotech, clinical lab, academia, and government sectors globally.

Stock Performance and Analyst Ratings

As of April 29, 2025, Revvity’s stock closed at $93.43. The company’s 52-week high was $129.5 on November 5, 2024, while the 52-week low was $88.53 on April 20, 2025. The price-to-earnings ratio stood at 34.2313.

On May 1, 2025, UBS upgraded Revvity’s stock rating to “Buy” and adjusted the price target to $115. This follows a previous rating by Stifel, which maintained a “Hold” rating with a $120 target as of April 29, 2025.

Earnings and Financial Performance

Revvity’s first-quarter 2025 earnings call highlighted a strong performance, surpassing Wall Street expectations. The company reported a 4% organic growth, driven by robust diagnostics performance. Analysts noted that Revvity delivered better-than-expected earnings, maintaining its full-year profit forecast despite an evolving macroeconomic backdrop.

The company’s strong demand for medical equipment contributed to its financial success, as noted in multiple reports. Revvity’s ability to exceed quarterly estimates has been a key factor in its positive financial outlook.

Upcoming Investor Conferences

Revvity is set to present at upcoming investor conferences, as announced on April 30, 2025. These presentations will provide further insights into the company’s strategic direction and future initiatives.

Conclusion

Revvity Inc. continues to demonstrate resilience and growth in the competitive health care sector. With positive analyst ratings and strong earnings performance, the company is well-positioned to capitalize on its technological advancements and market demand. For more information, stakeholders can visit Revvity’s website at www.revvity.com .